Keros Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapeutics targeting the transforming growth factor-beta (TGF-ß) superfamily of proteins. The company focuses on creating treatments for patients with hematological and neuromuscular disorders linked to dysfunctional protein signaling.
Subscribe to see Keros’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Keros is a biotech company headquartered in United States. Its most recent funding round, Series C, raised $56M in March 2020. Xcout tracks 11 named people at Keros, including Jasbir Seehra, Ph.D. (President, Chief Executive Officer and Director). Xcout recorded 37 job postings from Keros in the last 90 days.
5 more named people on record for Keros, with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $56M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Xcout recorded 37 job postings from Keros in the last 90 days, from a hiring record Xcout has kept since July 2026.
The weekly hiring trend, the roles and locations behind it — see Keros's hiring signals →
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.